scPharmaceuticals (NASDAQ:SCPH) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

Separately, Craig Hallum reduced their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday.

scPharmaceuticals Trading Up 3.0 %

NASDAQ:SCPH opened at $3.46 on Thursday. scPharmaceuticals has a 52 week low of $3.08 and a 52 week high of $6.71. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.66 and a current ratio of 8.08. The stock’s fifty day moving average is $4.46 and its two-hundred day moving average is $4.48.

scPharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $8.05 million during the quarter, compared to the consensus estimate of $8.04 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, equities research analysts predict that scPharmaceuticals will post -1.37 EPS for the current year.

Institutional Investors Weigh In On scPharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in shares of scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after buying an additional 3,101 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals in the 3rd quarter valued at $57,000. MetLife Investment Management LLC increased its stake in shares of scPharmaceuticals by 135.0% during the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock worth $77,000 after purchasing an additional 9,752 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of scPharmaceuticals during the 1st quarter worth about $90,000. Finally, Captrust Financial Advisors boosted its holdings in scPharmaceuticals by 32.2% in the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after purchasing an additional 4,513 shares during the period. 89.52% of the stock is currently owned by institutional investors.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.